Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immune cell predictors in concurrent chemoradiotherapy followed by PD-1 inhibitor for locally advanced cervical cancer
ChiCTR2200056704Phase 2Not yet recruiting
- Sponsor
- Renji Hospital
- Start
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel and cisplatin in Cervical Cancer (CC), sponsored by Renji Hospital. Primary endpoint: Predictive value of immune cell subsets for treatment outcome. Planned start Feb 2022; status: not yet recruiting.
02
Drugs
paclitaxelcisplatin
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on ChiCTR2200056704.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200056704.